Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed inferior relapse-free and overall survival, however, these mutations did not represent independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 patients revealed an isoform expression profile which is highly characteristic for each individual mutation, with several isoforms showing a strong dysregulation. By establishing a custom differential splice junction usage pipeline, we accurately detected aberrant splicing in splicing factor mutated samples. A large proportion of differentially used junctions were novel, including several junctions in leukemia-associated genes. In SRSF2(P95H) mutants, we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Furthermore, we observed a validated impact on overall survival for two junctions overused in SRSF2(P95H) mutants. We conclude that splicing factor mutations do not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Leukemia - 34(2020), 10 vom: 01. Okt., Seite 2621-2634 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bamopoulos, Stefanos A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.11.2020 Date Revised 18.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-020-0839-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30942187X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30942187X | ||
| 003 | DE-627 | ||
| 005 | 20231225133856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-020-0839-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM30942187X | ||
| 035 | |a (NLM)32358566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bamopoulos, Stefanos A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.11.2020 | ||
| 500 | |a Date Revised 18.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed inferior relapse-free and overall survival, however, these mutations did not represent independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 patients revealed an isoform expression profile which is highly characteristic for each individual mutation, with several isoforms showing a strong dysregulation. By establishing a custom differential splice junction usage pipeline, we accurately detected aberrant splicing in splicing factor mutated samples. A large proportion of differentially used junctions were novel, including several junctions in leukemia-associated genes. In SRSF2(P95H) mutants, we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Furthermore, we observed a validated impact on overall survival for two junctions overused in SRSF2(P95H) mutants. We conclude that splicing factor mutations do not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Phosphoproteins |2 NLM | |
| 650 | 7 | |a RNA Splicing Factors |2 NLM | |
| 650 | 7 | |a SF3B1 protein, human |2 NLM | |
| 650 | 7 | |a Splicing Factor U2AF |2 NLM | |
| 650 | 7 | |a U2AF1 protein, human |2 NLM | |
| 650 | 7 | |a SRSF2 protein, human |2 NLM | |
| 650 | 7 | |a 147153-65-9 |2 NLM | |
| 650 | 7 | |a Serine-Arginine Splicing Factors |2 NLM | |
| 650 | 7 | |a 170974-22-8 |2 NLM | |
| 700 | 1 | |a Batcha, Aarif M N |e verfasserin |4 aut | |
| 700 | 1 | |a Jurinovic, Vindi |e verfasserin |4 aut | |
| 700 | 1 | |a Rothenberg-Thurley, Maja |e verfasserin |4 aut | |
| 700 | 1 | |a Janke, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Ksienzyk, Bianka |e verfasserin |4 aut | |
| 700 | 1 | |a Philippou-Massier, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Graf, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Krebs, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Blum, Helmut |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Konstandin, Nikola |e verfasserin |4 aut | |
| 700 | 1 | |a Sauerland, Maria Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Görlich, Dennis |e verfasserin |4 aut | |
| 700 | 1 | |a Berdel, Wolfgang E |e verfasserin |4 aut | |
| 700 | 1 | |a Woermann, Bernhard J |e verfasserin |4 aut | |
| 700 | 1 | |a Bohlander, Stefan K |e verfasserin |4 aut | |
| 700 | 1 | |a Canzar, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Mansmann, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Hiddemann, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Braess, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e verfasserin |4 aut | |
| 700 | 1 | |a Metzeler, Klaus H |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Tobias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 34(2020), 10 vom: 01. Okt., Seite 2621-2634 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:2621-2634 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-020-0839-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 10 |b 01 |c 10 |h 2621-2634 | ||